Bharat Biotech International (BBIL) has inaugurated India’s only vertically integrated cell & gene therapy (C>) infrastructure & viral vector production facility in Genome Valley with a USD 75 million investment.
Spanning 50,000 sq. ft., the GMP-certified facility includes a clean room environment and will address unmet clinical needs worldwide, particularly in hematological malignancies and inherited blood disorders.
The new facility will focus on oncology and rare disease treatments, including CD19 CAR T cell therapy for blood cancers and gene therapy. Krishanu Saha from the University of Wisconsin-Madison revealed his lab’s collaboration with Bharat Biotech to develop AI-driven CAR cell therapies.
Executive Chairman Krishan Ella emphasised the company’s transition beyond vaccines to regenerative and personalised therapies, stating, “With this, we are moving beyond vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.” The company, which has conducted around 150 clinical trials in 20 countries, aims to translate advanced scientific discoveries into real-world solutions.